Company news
Arch Biopartners, Inc. (TSXV:ARCH) news
Arch Biopartners, Inc. news releases on 6ix. Latest, Aug 31, 2026: Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac…
Press releases & updates
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
August 31, 2026
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
August 11, 2026
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
July 17, 2026
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
June 4, 2026
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
May 22, 2026
Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI
April 30, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
March 24, 2026
Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
March 20, 2026
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
February 9, 2026
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
January 16, 2026
Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
December 16, 2025
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
December 16, 2025
Arch Biopartners Closes Non-Brokered Private Placement
November 19, 2025
Arch Biopartners Arranges Non-Brokered Private Placement
November 10, 2025
Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
November 5, 2025
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)
September 17, 2025
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
August 6, 2025
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
July 22, 2025
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
April 22, 2025
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)
February 18, 2025
InvestmentPitch Media Video Discusses Arch Biopartners' Awarding of $6.7 Million from Canadian Government's Strategic Innovation Fund - Video Available on Investmentpitch.com
December 17, 2020
IIROC Trading Resumption - ARCH
December 15, 2020
IIROC Trading Halt - ARCH
December 15, 2020
Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials
September 26, 2018
Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok
August 14, 2018
Investment Industry Regulatory Organization of Canada - Trade Resumption - Artha Resources Corp. - ACH
August 19, 2009